Search

Vir Biotechnology Inc

Lezárt

SzektorEgészségügy

11.7 5.31

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

10.89

Maximum

11.94

Fő mutatók

By Trading Economics

Bevétel

206M

80M

Értékesítés

239M

239M

Egy részvényre jutó nyereség

0.47

Profit margin

33.514

Munkavállalók

367

EBITDA

201M

78M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+91.42% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 4.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

492M

2B

Előző nyitás

6.39

Előző zárás

11.7

Vir Biotechnology Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 9. 20:02 UTC

Correlated Moves
Event
Social Media

Vir Biotechnology receives FDA Fast Track designation for VIR-5500, a PSMA-targeted treatment for metastatic castration-resistant prostate cancer.

2026. okt. 8. 21:01 UTC

Event

Vir Biotechnology receives FDA Fast Track designation for its investigational treatment VIR-5500 for late-line metastatic castration-resistant prostate cancer.

2026. okt. 7. 20:07 UTC

News
Social Media

Vir Biotechnology's shares fell following the announcement of David Liu as Chief Medical Officer, despite HC Wainwright reaffirming a Buy rating with a $22 price target.

2026. okt. 6. 20:40 UTC

Vir Biotechnology Inc has advanced in after-market trading, rebounding from earlier lows and achieving its highest cumulative return since Tuesday's close.

2026. okt. 5. 20:01 UTC

Vir Biotechnology Inc is trading sharply higher, reaching a cumulative return of nearly 6%, near the upper end of its one-month trading range.

2026. okt. 2. 20:07 UTC

Vir Biotechnology Inc shares fell sharply, continuing a decline from Thursday's close, despite rebounding earlier in the session.

2026. okt. 1. 20:13 UTC

Vir Biotechnology Inc is advancing in after-market trading, holding steady above its 20-day moving average with a cumulative return since Thursday's close.

2026. szept. 30. 22:56 UTC

Vir Biotechnology Inc traded modestly lower in after-market hours, continuing a downward trend since Wednesday's close, despite remaining above its 20-day moving average.

2026. szept. 29. 20:02 UTC

News

Vir Biotechnology is advancing after partnering with Astellas, securing $335 million to enhance its PRO-XTEN platform and support its Phase 3 hepatitis delta program.

2026. szept. 25. 19:55 UTC

Vir Biotechnology Inc shares fell, continuing a decline over the past three sessions, and remain below Thursday's close and the 20-day moving average.

2026. szept. 24. 20:07 UTC

Vir Biotechnology Inc's shares are declining, continuing a downward trend since Wednesday, amid notable selling pressure and unfavorable broader market conditions.

2026. szept. 23. 20:31 UTC

Vir Biotechnology Inc experienced a notable decline in after-market trading, reaching a low and positioned around the middle of its one-month trading range.

2026. szept. 22. 23:31 UTC

Vir Biotechnology Inc has seen a significant decline during after-market trading, with volatility indicating a sharp downturn since Tuesday's close.

2026. szept. 21. 20:31 UTC

Vir Biotechnology Inc has advanced in after-market trading, reaching its highest cumulative return since Monday's close and positioned above its 20-day moving average.

2026. szept. 18. 19:55 UTC

Vir Biotechnology Inc shares fell sharply, reaching their lowest point around midday and remaining notably below the 20-day moving average.

2026. szept. 17. 20:07 UTC

Correlated Moves

Vir Biotechnology is higher amid a biotech sector rally, supported by the SPDR S&P Biotech ETF's rise following Moderna's positive cancer vaccine results.

2026. szept. 16. 23:06 UTC

Vir Biotechnology Inc is trading modestly higher during after-market hours, continuing a routine pattern with limited fluctuations since Wednesday's close.

2026. szept. 15. 23:41 UTC

Vir Biotechnology Inc shares are lower in after-market hours, following a broader market decline linked to a drop in the New York Empire State Manufacturing Index.

2026. szept. 14. 20:13 UTC

Vir Biotechnology Inc shares are higher in after-market hours, continuing a trend of three consecutive sessions in the same direction. No specific news was identified.

2026. szept. 11. 20:08 UTC

Vir Biotechnology Inc shares are higher during Friday's session, reflecting broader market trends. The stock experienced volatility, reaching a high shortly after the open.

2026. szept. 9. 20:07 UTC

Vir Biotechnology Inc shares are lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

2026. szept. 3. 19:46 UTC

Vir Biotechnology Inc shares are lower during Thursday's session, reversing early gains amid significant volatility. No specific news was identified to explain the decline.

2026. szept. 2. 23:16 UTC

Vir Biotechnology shares are lower in after-market trading, despite strong one-month performance. The stock remains above its 20-day moving average.

2026. szept. 1. 22:06 UTC

Social Media

Vir Biotechnology Inc. has a market cap of $1.6 billion and cash of $1 billion. Shares are higher in after-market trading following recent strong performance.

2026. aug. 28. 20:08 UTC

Vir Biotechnology Inc shares are lower today, continuing a decline since Thursday amid rising U.S. Treasury yields and broader market pressures.

2026. aug. 27. 20:08 UTC

Vir Biotechnology Inc shares are higher, reflecting a steady upward trend since Wednesday. Broader market conditions may be contributing to this positive movement.

2026. aug. 26. 20:08 UTC

Vir Biotechnology Inc is higher in Wednesday's session, continuing its upward trend since Tuesday's close, despite earlier fluctuations in price.

2026. aug. 25. 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

2026. aug. 24. 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

2026. aug. 21. 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

Társak összehasonlítása

Árváltozás

Vir Biotechnology Inc Előrejelzés

Célár

By TipRanks

91.42% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 21.286 USD  91.42%

Magas 30 USD

Alacsony 15 USD

8 Wall Street elemző 12 hónapos célárain alapulva a(z)Vir Biotechnology Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

8 ratings

8

Vétel

0

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.